Abstract:Abstract Background Epigenetic clocks are biomarkers of ageing derived from DNA methylation levels at a subset of CpG sites. The difference between age predicted by these clocks and chronological age, termed “epigenetic age acceleration”, has been shown to predict age-related disease and mortality. We aimed to assess the prognostic value of epigenetic age acceleration and a DNA methylation-based mortality risk score with all-cause mortality in a prospective clinical cohort of individuals with head and neck cancer: Head and Neck 5000. We investigated two markers of intrinsic epigenetic age acceleration ( IEAAHorvath and IEAAHannum ), one marker of extrinsic epigenetic age acceleration ( EEAA ), one optimised to predict physiological dysregulation ( AgeAccelPheno ), one optimised to predict lifespan ( AgeAccelGrim ) and a DNA methylation-based predictor of mortality ( ZhangScore ). Cox regression models were first used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations of epigenetic age acceleration with all-cause mortality in people with oropharyngeal cancer ( n = 408; 105 deaths). The added prognostic value of epigenetic markers compared to a clinical model including age, sex, TNM stage and HPV status was then evaluated. Results IEAAHannum and AgeAccelGrim were associated with mortality risk after adjustment for clinical and lifestyle factors (HRs per standard deviation [SD] increase in age acceleration = 1.30 [95% CI 1.07, 1.57; p = 0.007] and 1.40 [95% CI 1.06, 1.83; p = 0.016], respectively). There was weak evidence that the addition of AgeAccelGrim to the clinical model improved 3-year mortality prediction (area under the receiver operating characteristic curve: 0.80 vs. 0.77; p value for difference = 0.069). Conclusion In the setting of a large, clinical cohort of individuals with head and neck cancer, our study demonstrates the potential of epigenetic markers of ageing to enhance survival prediction in people with oropharyngeal cancer, beyond established prognostic factors. Our findings have potential uses in both clinical and non-clinical contexts: to aid treatment planning and improve patient stratification.

ERJ advances: epigenetic ageing and leveraging DNA methylation in chronic respiratory diseases

The Blood DNA Methylation Clock GrimAge Is a Robust Surrogate for Airway Epithelia Aging

Role of epigenetic mechanisms in the pathogenesis of chronic respiratory diseases and response to inhaled exposures: From basic concepts to clinical applications

Utility of DNA Methylation as a Biomarker in Aging and Alzheimer's Disease

DNA methylation-based biomarkers and the epigenetic clock theory of ageing

LSC - 2024 - Epigenetic age acceleration and severity of airflow limitation on blood and lung tissue of COPD

Epigenomic targets for the treatment of respiratory disease

DNA methylation age as a biomarker for cancer

An epigenetic biomarker of aging for lifespan and healthspan

EPIGENETICS MARKERS OF AGING AND EXPOSURES

An update on epigenetics and childhood respiratory diseases

Epigenetic blood biomarkers of ageing and mortality in COPD

DNA Methylation: A Potential Biomarker of Chronic Obstructive Pulmonary Disease

Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease

EPIGENETIC PREDICTORS OF LIFESPAN AND HEALTHSPAN

Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer

Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing

Epigenetic Predictor of Age

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

DNA methylation in genes of longevity-regulating pathways: association with obesity and metabolic complications

Epigenetic clocks in neurodegenerative diseases: a systematic review